Intellia Therapeutics (NTLA) Accumulated Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Accumulated Expenses for 12 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 77.15% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (down 77.15% YoY), while the FY2025 annual figure was $49.9 million, down 9.92% from the prior year.
• Accumulated Expenses fell to $9.3 million in Q1 2026 per NTLA's latest filing, from $49.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $67.0 million in Q4 2023 and bottomed at $9.3 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $31.5 million across 5 years, with a median of $21.8 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 301.99% — and 2026, when it plunged 77.15%.
• Intellia Therapeutics' Accumulated Expenses stood at $21.8 million in 2022, then surged by 207.73% to $67.0 million in 2023, then fell by 17.4% to $55.4 million in 2024, then retreated by 9.92% to $49.9 million in 2025, then tumbled by 81.3% to $9.3 million in 2026.
• Business Quant data shows NTLA's Accumulated Expenses at $9.3 million in Q1 2026, $49.9 million in Q4 2025, and $16.8 million in Q3 2025.